Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Absci CorpABSI · Entity 4685 | Chief Legal Officer | March 02, 2026 | March 16, 2026 |
| Korro Bio, Inc.KRRO · Entity 6388 | See Remarks | November 03, 2023 | November 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Absci Corp
Report date March 02, 2026 · Filed March 16, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,775 |
Last balance in matching sequence
After 2026-03-03 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-03-02 · Grant · Acquired 90,300 · Balance 149,600 F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. The RSUs shall vest and be settled in three substantially equal annual installments with the first such annual installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Row 2 · 2026-03-03 · Tax withholding · Disposed 9,825 · Balance 139,775 F2: Amount reported represents the number of shares withheld by the Issuer to cover the tax withholding obligation in connection with the vesting of these restricted stock units and does not represent a discretionary trade by the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2036-03-01 | Direct | 356,300 |
Reported balance
After 2026-03-02 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2026-03-02 · Grant · Acquired 356,300 · Balance 356,300 F3: The shares subject to this option shall vest and become exercisable over a three year period, in substantially equal annual installments with the first such installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. The RSUs shall vest and be settled in three substantially equal annual installments with the first such annual installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2: Amount reported represents the number of shares withheld by the Issuer to cover the tax withholding obligation in connection with the vesting of these restricted stock units and does not represent a discretionary trade by the reporting person.
F3: The shares subject to this option shall vest and become exercisable over a three year period, in substantially equal annual installments with the first such installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.
Korro Bio, Inc.
Report date November 03, 2023 · Filed November 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.94 · Expires 2033-05-22 | Direct | 23,723 |
Reported balance
After 2023-11-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-03 · Grant · Acquired 23,723 · Balance 23,723 F1: Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. F2: (Continued from footnote 1) 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. F4: Received in exchange for a stock option to acquire 477,453 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement. F3: The shares subject to the option vest as to 25% of the shares on May 8, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.98 · Expires 2033-11-02 | Direct | 29,061 |
Reported balance
After 2023-11-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-03 · Grant · Acquired 29,061 · Balance 29,061 F5: The shares subject to the option vest in 48 equal monthly installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc.
F2: (Continued from footnote 1) 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc.
F3: The shares subject to the option vest as to 25% of the shares on May 8, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F4: Received in exchange for a stock option to acquire 477,453 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement.
F5: The shares subject to the option vest in 48 equal monthly installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 02:14 UTC | Absci Corp ABSI · Entity 4685 | Tax withholdingCommon Stock | 9,825 | $2.80 | $27,510.00 |
DisclosureSEC source: 0001672688-26-000040 · wk-form4_1772676849.xml · nonDerivative · entry 2 Walker Shelby J. · CIK 0001997919 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,775 F2 · shares: Amount reported represents the number of shares withheld by the Issuer to cover the tax withholding obligation in connection with the vesting of these restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2026 Filed Mar 16, 2026 22:56 UTC Amendment | Absci Corp ABSI · Entity 4685 | Tax withholdingCommon Stock | 9,825 | $2.80 | $27,510.00 |
DisclosureSEC source: 0001672688-26-000058 · wk-form4a_1773701789.xml · nonDerivative · entry 2 Walker Shelby J. · CIK 0001997919 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,775 F2 · shares: Amount reported represents the number of shares withheld by the Issuer to cover the tax withholding obligation in connection with the vesting of these restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 02:14 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 356,300 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001672688-26-000040 · wk-form4_1772676849.xml · derivative · entry 3 Walker Shelby J. · CIK 0001997919 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,300 Underlying: Common Stock · 356,300 shares Expires 2036-02-29 F3 · shares: The shares subject to this option shall vest and become exercisable over a three year period, in substantially equal annual installments with the first such installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable over a three year period, in substantially equal annual installments with the first such installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 02:14 UTC | Absci Corp ABSI · Entity 4685 | GrantCommon Stock | 90,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001672688-26-000040 · wk-form4_1772676849.xml · nonDerivative · entry 1 Walker Shelby J. · CIK 0001997919 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,600 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. The RSUs shall vest and be settled in three substantially equal annual installments with the first such annual installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 02, 2026 Filed Mar 16, 2026 22:56 UTC Amendment | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 356,300 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001672688-26-000058 · wk-form4a_1773701789.xml · derivative · entry 3 Walker Shelby J. · CIK 0001997919 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,300 Underlying: Common Stock · 356,300 shares Expires 2036-03-01 F3 · shares: The shares subject to this option shall vest and become exercisable over a three year period, in substantially equal annual installments with the first such installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable over a three year period, in substantially equal annual installments with the first such installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 02, 2026 Filed Mar 16, 2026 22:56 UTC Amendment | Absci Corp ABSI · Entity 4685 | GrantCommon Stock | 90,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001672688-26-000058 · wk-form4a_1773701789.xml · nonDerivative · entry 1 Walker Shelby J. · CIK 0001997919 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,600 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. The RSUs shall vest and be settled in three substantially equal annual installments with the first such annual installment vesting on March 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:43 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 234,200 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001672688-25-000019 · wk-form4_1741128180.xml · derivative · entry 2 Walker Shelby J. · CIK 0001997919 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,200 Underlying: Common Stock · 234,200 shares Expires 2035-03-02 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable over a three year period, in substantially equal annual installments with the first such installment vesting on March 3, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:43 UTC | Absci Corp ABSI · Entity 4685 | GrantCommon Stock | 59,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001672688-25-000019 · wk-form4_1741128180.xml · nonDerivative · entry 1 Walker Shelby J. · CIK 0001997919 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,300 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Absci Corporation 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest and be settled in three substantially equal annual installments with the first such annual installment vesting on March 3, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:48 UTC | Absci Corp ABSI · Entity 4685 | GrantStock Option (right to buy) · Derivative | 613,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001672688-24-000034 · wk-form4_1720039679.xml · derivative · entry 1 Walker Shelby J. · CIK 0001997919 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613,000 Underlying: Common Stock · 613,000 shares Expires 2034-06-30 F1 · derivative.exercise_date: Grant to the Reporting Person as a material inducement to employment under the Issuer's 2023 Inducement Plan. 25% of the shares subject to this option vest and become exercisable on June 27, 2025, and the remaining 75% of the shares subject to this option vest and become exercisable in 36 approximately equal monthly installments thereafter, until June 27, 2028, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 03, 2023 Filed Nov 8, 2023 02:16 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 29,061 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0000950170-23-060610 · ownership.xml · derivative · entry 2 Walker Shelby J. · CIK 0001997919 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,061 Underlying: Common Stock · 29,061 shares Expires 2033-11-02 F5 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments commencing from November 3, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 03, 2023 Filed Nov 8, 2023 02:16 UTC | Korro Bio, Inc. KRRO · Entity 6388 | GrantStock Option (Right to Buy) · Derivative | 23,723 | Not disclosed Strike: $21.94 | Not disclosed |
DisclosureSEC source: 0000950170-23-060610 · ownership.xml · derivative · entry 1 Walker Shelby J. · CIK 0001997919 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,723 Underlying: Common Stock · 23,723 shares Expires 2033-05-22 F1 · derivative.exercise_price: Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. F2 · derivative.exercise_price: (Continued from footnote 1) 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. F1 · kind: Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. F2 · kind: (Continued from footnote 1) 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. F1 · shares: Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. F2 · shares: (Continued from footnote 1) 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. F1 · price: Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. F2 · price: (Continued from footnote 1) 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. F4 · price: Received in exchange for a stock option to acquire 477,453 shares of Legacy Korro common stock issued under the 2019 Plan pursuant to the Merger Agreement. F3 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on May 8, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.underlying_shares: Under the terms of an Agreement and Plan of Merger dated as of July 14, 2023 by and among Korro Bio Ops, Inc. (f/k/a Korro Bio, Inc., "Legacy Korro"), the Issuer (f/k/a Frequency Therapeutics, Inc.) and Frequency Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), on November 3, 2023, Merger Sub merged with and into Legacy Korro (the "Merger"), with Legacy Korro surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Korro common stock issued under the Korro Bio, Inc. F2 · derivative.underlying_shares: (Continued from footnote 1) 2019 Stock Incentive Plan (the "2019 Plan") was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, at an exchange ratio of 0.049688 per share, on the same terms and conditions as were applicable under the 2019 Plan prior to the Merger, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-50. Subsequent to the Merger, the name of the Issuer was changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.